Vertaling van "n’est pas close " (Frans → Nederlands) :

TERMINOLOGIE

agoniste (a. et n.) | exerçant l'action principalev (muscle-)
agonist | spier die zelfstandig werkt

obésité (n) | obésité
obesitas | vetzucht

préclinique | où aucune manifestation clinique n'est encore décelable
preklinisch | voor de ziekte merkbaar wordt

pseudo-tumeur | qui présente les caractères cliniques d'une tumeur (mais n'est pas due à une prolifération de cellules)
pseudotumor | schijngezwel

nullipare (a et sf) | qui n'a pas eu d'enfant
nullipara | vrouw die nog geen kind heeft gebaard

contrast medium (n) | produit de contraste
contrastmiddel | constrast-stof | stof waarmee organen zichtbaar kunnen worden gemaakt

anovulatoire | qui n'est pas accompagné d'ovulation
anovulair | anovulatoor | zonder eisprong

antidépresseur (n.m et a.) | antidépressif
antidepressivum | middel tegen ziekelijke neerslachtigheid

atoxique (a) | qui n'est pas toxique
atoxisch | niet-giftig

psychose | maladie mentale dont le malade n'a pas conscience
psychose | geestelijke stoornis

IN-CONTEXT TRANSLATIONS

au point 1.9 (Les bâtiments de l’exploitation sont-ils inaccessibles aux oiseaux externes ?), de préciser de quels bâtiments il s’agit (poulaillers, exploitation, habitation, etc) et d’introduire dans cette question la structure au niveau de laquelle sont stockés la paille et/ou le lisier, qui peuvent éventuellement héberger le virus et être en contact avec les oiseaux externes si elle n’est pas close ;
in punt 1.9 (Zijn de bedrijfsgebouwen vogeldicht ?) aangeven om welke gebouwen het gaat (pluimveestallen, bedrijf, woning, enz) en in deze vraag de structuur verwerken waar stro en/of mengmest worden opgeslagen waarin het virus eventueel kan voorkomen en die in contact kan komen met vogels van buiten als ze niet gesloten is ;

It is therefore closely related to appropriateness, which can be defined as “the degree to which provided healthcare is relevant to the clinical
It is therefore closely related to appropriateness, which can be defined as “the degree to which provided healthcare is relevant to the clinical needs, given the current best evidence and the provider’s experience”. The link between effectiveness and appropriateness reflects the link

Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease perioperative risks ii . NICE Minor surgery: ASA I : not indicated ASA II : consider > 40 y if respiratory or CV disease ASA III : consider if respiratory or CV disease Intermediate surgery: ASA I : not indicated ASA II : consider if respiratory or CV disease (renal > 60y) ASA III : consider if respiratory, CV or renal disease Major surgery: ASA I : consider > 60 ASA II : consider if respiratory, CV or renal disease ASA III : consider if respiratory, CV or renal disease
Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease

Lorsque l’avis du comité doit être obtenu par procédure écrite, ladite procédure est close sans résultat lorsque, dans le délai imparti pour la formulation de l’avis, le président du comité le décide ou une majorité simple des membres du comité le demande.
Wanneer het advies van het comité via een schriftelijke procedure dient te worden verkregen, wordt die procedure zonder gevolg beëindigd indien, binnen de termijn voor het uitbrengen van het advies, door de voorzitter van het comité daartoe wordt besloten of door een eenvoudige meerderheid van de leden van het comité daarom wordt verzocht.

EPSU-HOSPEEM Closing confererence of joint project to promote the implementation and use of Directive 2010/32/EU ES Barcelona, 20/06/2013
EPSU-HOSPEEM Closing confererence of joint project to promote the implementation and use of Directive 2010/32/EU ES Barcelona, 20-06-2013

Closing conference of the 9th Initiative on ENWHIP - PH Work Promoting Health Work for people with Chronic Illness BE Brussels, 22/10/2013
Closing conference of the 9th Initiative on ENWHIP - PH Work Promoting Health Work for people with Chronic Illness BE Brussels, 22-10-2013

Avis n° 8292. Desai N, Xu J, AbdelHafez F. Vitrification carriers and DNA damage: open versus closed systems for cryopreservation of cleavage and blastocyt stage embryos.
Desai N, Xu J, AbdelHafez F. Vitrification carriers and DNA damage: open versus closed systems for cryopreservation of cleavage and blastocyt stage embryos.

vitrification/warming using to different closed carrier systems. Hum Reprod Suppl, in press 2010.
vitrification/warming using to different closed carrier systems Hum Reprod Suppl, in press 2010.

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

Closing Conference of the ETUCE Project " Teacher Trade Unions in Solidarity for Healthy and Safe Workplaces in the Economic Crisis" ES Madrid, 10/10/2013
Closing Conference of the ETUCE Project " Teacher Trade Unions in Solidarity for Healthy and Safe Workplaces in the Economic Crisis" ES Madrid, 10-10-2013